Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets

BMC Public Health

Table 2 Disease input parameters for the scenarios

Scenarios	2020	2022	2023	2024	2025	2030
Treated
Standard of Care prior to 2022	930	960	960	960	960	960
Screening Program	930	1570	3700	960	960	960
WHO Elimination	930	1570	3700	2180	2180	2180
Viraemic newly diagnosed
Standard of Care prior to 2022	1520	1920	1920	1920	1920	1920
Screening Program	930	4360	7410	960	960	960
WHO Elimination	930	4360	7410	500	500	500
Liver fibrosis stage for treatment eligibility,
Standard of Care prior to 2022	≥F2	≥F2	≥F2	≥F2	≥F2	≥F2
Screening Program	≥F2	≥F2	≥F2	≥F2	≥F2	≥F2
WHO Elimination	≥F2	≥F2	≥F2	≥F0	≥F0	≥F0
Anti-HCV tests
Screening Program		460,250	851,380
WHO Elimination		460,250	851,380	488,370	740	270
Incident cases of chronic HCV*
Screening Program	610	580	570	560	550	500
WHO Elimination	610	580	570	520	450	160
Age limits for treatment eligibility*
Screening Program	15–74	15–74	15–74	15–74	15–74	15–74
WHO Elimination	15–74	15–74	15–74	15–84	15–84	15–84
Sustained virological response	99%	99%	99%	99%	99%	99%

ISSN: 1471-2458